Navigation Links
Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
Date:7/16/2008


CINCINNATI, July 16 /PRNewswire-FirstCall/ --

CALL DATE: Wednesday, Aug. 6, 2008

TIME: 9:30 a.m. Eastern Time

HOST: Dr. Candace Kendle, Chairman and CEO

Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast on Wednesday, Aug. 6 at 9:30 a.m. Eastern Time to discuss its financial results for the Second Quarter ended June 30, 2008. A question and answer session will follow.

Webcast Instructions

To access the live webcast, visit the company Web site at http://www.kendle.com or link to the Webcast directly at http://www.videonewswire.com/event.asp?id=50021 . Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Sept. 5, 2008. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx .

Conference Call Instructions

To register (RSVP) for the telephone conference call, U.S. and Canadian participants should dial (800) 223-7104. Participants outside North America should dial (706) 645-6519.

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on Sept. 5 by dialing (706) 645-9291 and entering conference ID number 55347808.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at http://www.kendle.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
2. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
3. Kendle Appoints Patricia Williams Vice President, Commercial Operations
4. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
5. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
6. Kendle Leaders Adopt 10b5-1 Trading Plans
7. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
8. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
9. Kendle to Present at the Wachovia 2008 Healthcare Conference
10. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
11. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):